Glenmark Pharma Gains on Growth Outlook

  Published 7 months ago

Glenmark shares rise 3.5% as HSBC retains "buy," citing growth drivers, approvals, and strong business momentum.

  • HSBC sees easing R&D, Monroe supplies, U.S. approvals, and India launches driving Glenmark’s strong future growth.
  • Stock remains bullish above 100-day and 200-day averages, marking the strongest session gains since July 11.
  • Analyst consensus remains "buy," with a median price target of ₹2,380, implying 19% upside from current.

You might like these

CCL Products Q1 Revenue Up 36% YoY

RBI Highlights Rising FY25-26 Deficits

Laxmi Organic: FY25 Results & Future Outlook

LG Electronics India IPO Highlights

Reliance Jio Q2FY26: 506M Users, Profit

Airtel’s AI Spam Defense Wins I4C Praise

United Breweries Closes Mangalore Brewery

News that matters the most ⚡